secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001140361-25-040675
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics raises $23M in direct offering and secures FDA guidance for LCA5 gene therapy trial
--------------------------------------------------------------------------------

- $23M registered direct offering led by Perceptive Advisors and Balyasny Asset Management; closes Nov 7, 2025.
- Offering: 3.83M shares at $2.09/sh and pre-funded warrants for 7.18M shares at $2.0899.
- FDA RMAT meeting provides guidance on registration strategy; Phase 3 design adaptive, as few as 8 participants.
- Phase 1/2 data: all 6 late-stage participants achieved clinically meaningful vision improvements.
- First participant enrolled in run-in; dosing H2 2026, topline ~1 year later; cash runway into H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125040675/0001140361-25-040675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125040675/ny20058362x4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer